Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL3987 Target Snapshot

Ephrin type-A receptor 5 · SINGLE PROTEIN · Homo sapiens

826Compounds
241Assays
14Approved Drugs
410.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Protein identity stays anchored to UniProt P54756. Use UniProt P54756 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt P54756 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Ephrin type-A receptor 5 as ChEMBL target CHEMBL3987, mapped to UniProt P54756. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Ephrin type-A receptor 5
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL3987
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P54756
Ephrin type-A receptor 5
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Ephrin type-A receptor 5 is the right protein anchor across sources, using UniProt P54756 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelEphrin type-A receptor 5
UniProt AccessionP54756
Component TypeProtein
Sequence Length1037 aa

Ephrin type-A receptor 5

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Ephrin type-A receptor 5, mapped to UniProt P54756. Sequence length is 1037 aa.

Mapped IDP54756
Review nameEphrin type-A receptor 5
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

14
Approved
5
Phase III
12
Phase II
6
Phase I
Assay Mix

Activity Type Distribution

IC5023.0
KD387.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL5416410 9.62 Kd 0.24 Approved
CHEMBL400402 9.4 Kd 0.4 Preclinical
CHEMBL1421 8.68 IC50 2.1 Approved
CHEMBL3752910 8.55 IC50 2.8 Preclinical
CHEMBL566515 8.52 IC50 3.0 Preclinical
CHEMBL249097 8.52 Kd 3.0 Preclinical
CHEMBL1421 8.44 Kd 3.664 Approved
CHEMBL1230609 8.18 Kd 6.6 Clinical
CHEMBL1171837 8.1 Kd 8.0 Approved
CHEMBL388978 7.99 IC50 10.3 Preclinical
Distribution

pChEMBL Value Distribution

9
5.0
19
5.5
15
6.0
11
6.5
8
7.0
6
7.5
5
8.0
5
8.5
1
9.0
2
9.5
pChEMBL
Approved Drugs

Approved Drugs

TIVOZANIB
CHEMBL1289494
Approved 2017
PONATINIB
CHEMBL1171837
Approved 2012
BOSUTINIB
CHEMBL288441
Approved 2012
VANDETANIB
CHEMBL24828
Approved 2011
CRIZOTINIB
CHEMBL601719
Approved 2011
DASATINIB
CHEMBL5416410
Approved 2006
DASATINIB ANHYDROUS
CHEMBL1421
Approved 2006
SORAFENIB
CHEMBL1336
Approved 2005
ERLOTINIB
CHEMBL553
Approved 2004
Assay Landscape

Assay Landscape

241
Total Assays
60
Tested Compounds
1
Assay Types
Binding — 241 assays, 60 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 198 37 6.6
assay format 24 1 8.6
cell-based format 14 3 8.0
subcellular format 5 19 6.7

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine